Downregulation of FoxM1 inhibits proliferation, invasion and angiogenesis of HeLa cells in vitro and in vivo

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2355-2364

  Chen, Hong ^a   Zou, Yang ^a   Yang, Hong ^a   Wang, Jingjing ^a   Pan, Hong ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Angiogenesis; FoxM1; Invasion; Migration; Tumorigenesis

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; GELATINASE A; GELATINASE B; VASCULOTROPIN A;

ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; HUMAN; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR INVASION; UTERINE CERVIX TUMOR;

ANIMALS; CELL PROLIFERATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84907697329     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2645     Document Type: Article

References (50)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer Statistics, 2014. CA Cancer J Clin 64:9-29, 2014.
2. Pectasides D, Kamposioras K, Papaxoinis G and Pectasides E: Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 34:603-613, 2008.
3. Li S, Hu T, Lv W, et al: Changes in prevalence and clinical characteristics of cervical cancer in the People's Republic of China: a study of 10, 012 cases from a nationwide working group. Oncologist 18:1101-1107, 2013.
4. Yee GP, de Souza P and Khachigian LM: Current and potential treatments for cervical cancer. Curr Cancer Drug Targets 13:205-220, 2013.
5. Ahmad A, Wang Z, Kong D, et al: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat 122:337-346, 2010.
6. Kim IM, Ackerson T, Ramakrishna S, et al: The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 66:2153-2161, 2006.
7. Liu M, Dai B, Kang SH, et al: FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 66:3593-3602, 2006.
8. Wang Z, Banerjee S, Kong D, Li Y and Sarkar FH: Downregulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 67:8293-8300, 2007.
9. Feng Y, Wang L, Zeng J, et al: FoxM1 is overexpressed in Helicobacter pylori-induced gastric carcinogenesis and is negatively regulated by miR-370. Mol Cancer Res 11:834-844, 2013.
10. Kalinichenko VV, Major ML, Wang X, et al: Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 18:830-850, 2004.
11. Chan DW, Yu SY, Chiu PM, et al: Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J Pathol 215:245-252, 2008.
12. Guan P, Chen H, Li HJ, Duan J and Chen JY: Expression and significance of FOXM1 in human cervical cancer: a tissue micro-array study. Clin Invest Med 34: E1-E7, 2011.
13. Khongkow P, Karunarathna U, Khongkow M, et al: FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. Oncogene: Oct. 21, 2013 (Epub ahead of print). doi: 10.1038/onc.2013.457.
14. Raychaudhuri P and Park HJ: FoxM1: a master regulator of tumor metastasis. Cancer Res 71:4329-4333, 2011.
15. Li Y, Ligr M, McCarron JP, et al: Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion. Clin Cancer Res 17:4414-4424, 2011.
16. Sun H, Teng M, Liu J, et al: FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria. Cancer Lett 306:214-222, 2011.
17. Li Q, Zhang N, Jia Z, et al: Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res 69:3501-3509, 2009.
18. Wierstra I and Alves J: FOXM1, a typical proliferation-associated transcription factor. Biol Chem 388:1257-1274, 2007.
19. Wang IC, Chen YJ, Hughes D, et al: Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 25:10875-10894, 2005.
20. Laoukili J, Kooistra MR, Bras A, et al: FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7:126-136, 2005.
21. Cao Y, E G, Wang E, et al: VEGF exerts an angiogenesisindependent function in cancer cells to promote their malignant progression. Cancer Res 72:3912-3918, 2012.
22. Naito S, von Eschenbach AC, Giavazzi R and Fidler IJ: Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46:4109-4115, 1986.
23. Kim YH, Kim MA, Park IA, et al: VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival. Gynecol Oncol 119:232-236, 2010.
24. Green DR and Evan GI: A matter of life and death. Cancer Cell 1:19-30, 2002.
25. Katoh M and Katoh M: Human FOX gene family (Review). Int J Oncol 25:1495-1500, 2004.
26. Ahmed M, Uddin S, Hussain AR, et al: FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma. J Clin Endocrinol Metab 97: E1-E13, 2012.
27. Uddin S, Ahmed M, Hussain A, et al: Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am J Pathol 178:537-547, 2011.
28. Chen X, Muller GA, Quaas M, et al: The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism. Mol Cell Biol 33:227-236, 2013.
29. Halasi M and Gartel AL: Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage. PLoS One 7: e31761, 2012.
30. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7:3113-3119, 2001.
31. Maatta M, Soini Y, Liakka A and Autio-Harmainen H: Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 6:2726-2734, 2000.
32. Klein G, Vellenga E, Fraaije MW, Kamps WA and de Bont ES: The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 50:87-100, 2004.
33. Passlick B, Sienel W, Seen-Hibler R, et al: Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 6:3944-3948, 2000.
34. Xue YJ, Xiao RH, Long DZ, et al: Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma. J Transl Med 10:200, 2012.
35. Dai B, Kang SH, Gong W, et al: Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene 26:6212-6219, 2007.
36. Gorantla B, Asuthkar S, Rao JS, Patel J and Gondi CS: Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol Cancer Res 9:377-389, 2011.
37. Raghu H, Nalla AK, Gondi CS, Gujrati M, Dinh DH and Rao JS: uPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells. Mol Oncol 6:33-47, 2012.
38. Pulukuri SM, Gondi CS, Lakka SS, et al: RNA interferencedirected knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280:36529-36540, 2005.
39. Zhao R, Liu XQ, Wu XP, et al: Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha (v) beta6. Cancer Lett 287:150-156, 2010.
40. Lee J, Lee J, Yu H, Choi K and Choi C: Differential dependency of human cancer cells on vascular endothelial growth factormediated autocrine growth and survival. Cancer Lett 309:145-150, 2011.
41. Risau W: Mechanisms of angiogenesis. Nature 386:671-674, 1997.
42. Folkman J: Angiogenesis. Annu Rev Med 57:1-18, 2006.
43. Zhang Y, Zhang N, Dai B, et al: FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res 68:8733-8742, 2008.
44. Cai Y, Balli D, Ustiyan V, et al: Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis. J Biol Chem 288:22527-22541, 2013.
45. No JH, Jo H, Kim SH, et al: Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia. Ann NY Acad Sci 1171:100-104, 2009.
46. Fang J, Shing Y, Wiederschain D, et al: Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA 97:3884-3889, 2000.
47. Silletti S, Kessler T, Goldberg J, Boger DL and Cheresh DA: Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 98:119-124, 2001.
48. Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao JS and Lakka S: Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther 5:2289-2299, 2006.
49. Chetty C, Lakka SS, Bhoopathi P and Rao JS: MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer 127:1081-1095, 2010.
50. He SY, Shen HW, Xu L, et al: FOXM1 promotes tumor cell invasion and correlates with poor prognosis in early-stage cervical cancer. Gynecol Oncol 127:601-610, 2012.